OXFORD GASTRO-OESOPHAGEAL SYMPOSIUM

He is the National Lead in Ireland for Oesophageal and Gastric cancer. He
is Cancer Clinical Lead at the Trinity St James’s Cancer Institute. He is President of the Irish Society of
Clinical Nutrition and Metabolism (IRSPEN). He is President of the European Society of Diseases of
the Oesophagus (ESDE). He is on the Editorial Board of the European Surgical Association (ESA). He is
on the Accreditation and Designation Board of the Organisation of European Cancer Institutes (OECI).
Professor Reynolds has published widely in predominantly cancer research, with approximately 500
peer-reviewed publications, and over €6m research grant income.

Research is focused on
outcomes after surgery for gastric and oesophageal cancer and clinical studies on neoadjuvant
treatment for oesophageal and gastric cancer. Dr. Wijnhoven is editor for BJS (British Journal of
Surgery) since 2014. He has authored and co-authored over 350 articles in national and international
peer-reviewed journals.

His main clinical and scientific interests are gastric and oesophageal cancer with particular focus on minimally invasive surgical techniques, adjunct oncological therapies, new therapies for peritoneal metastases and management of surgical complications. Dr Nilsson is the past President of the European Society for Diseases of the Esophagus, the Swedish Society of Upper Abdominal Surgery and currently the
Chairman of the Swedish National Registry for Gastric and Esophageal Cancer. Dr Nilsson has a strong focus on multidisciplinary collaboration in cancer care and research and is a faculty member of the upper gastrointestinal group of the European Society for Medical Oncology (ESMO) and a member of the European Organization for Research and Treatment of Cancer (EORTC) gastrointestinal group. Dr
Nilsson is Editor-in Chief of the journal Diseases of the Esophagus.

He is director of the Division of Thoracic and Upper Gastrointestinal Surgery and heads the Upper Gastrointestinal Cancer Program at McGill University. Dr Ferri couples this clinical activity with an active translational and fundamental research program investigating the mechanisms of therapy resistance in gastro-esophageal adenocarcinoma and the inflammatory basis of cancer progression for which he is the recipient of numerous peer review grants from the Canadian Institutes of Health Research, Canadian Cancer Society, United States Department of Defense, and a Grand Challenge from Cancer Research UK.

He was appointed consultant OG surgeon at the Royal Victoria Infirmary,
Newcastle-upon-Tyne in 2001. He took up his current position in 2006, as Head of Department in Guildford, where he has built a 5-consultant lead OG team, that has pioneered minimal access surgery, enhanced recovery, pre-habilitation and more recently robotic surgery. The Unit serves a population of 4.5 million people across Surrey and Sussex. As an early adopter of Endoscopic Ultrasound, he has taught many others.
His Fellowship was at the National Cancer Center Hospital, Tokyo in 2001, improving his radical OG surgery. After visiting Professor JD Luketich, University of Pittsburgh Medical Center (UPMC) in 2006, he established a MIO programme. In 2011, with his team and Dr Don Low, Virginia Mason Medical Center, Seattle, they developed the first ERAS & Standardised Clinical Pathway for oesophageal cancer surgery in the UK.
Mr Preston’s obtained his Doctorate (University of Leeds) in 1997 and has maintained an active
interest in research. He was National Chief Investigator on the Neo-AEGIS trial, recently published in The Lancet – Gastroenterology & Hepatology (2023) and was Principal Investigator in the OCCAMS
Consortium that has vastly expanded our understanding of oesophageal and junctional
adenocarcinoma.

She is lead investigator for a Health Research and Irish Cancer Society funded research programme on nutrition in survivorship following oesophagogastric cancer surgery, including the international multicentre ENSURE study and European SARONG-II RCT. Jessie has a major interest in clinical and translational research to improve outcomes for patients with oesophagogastric cancer. Her research focuses on nutrition, survivorship and implementation of minimally invasive cancer surgery.

He performed Hong Kong’s first ESD and POEM in 2004 and 2010, respectively. In 2011 he pioneered world’s first robotic gastric ESD,
followed by first robotic colorectal ESD in 2020. He is a founding member of the Upper GI
International Robotic Association which fosters effective implementation and advancement of
robotic esophagectomy worldwide. He was bestowed Honorary Membership of the European Association of Endoscopic Surgery and Karl-Storz-Harold Hopkins Golden Telescope Award in 2023.

Dr. Pouw’s clinical work focusses on
offering a wide range of endoscopic treatments to patients with upper gastrointestinal neoplasia.
Furthermore, she supervises several research lines on endoscopic management of early Barrett’s neoplasia and endoscopic vacuum therapy for treatment of defects in the upper gastrointestinal tract.
Dr. Pouw is active as board member for several (inter-)national societies, such as Young International Society for Diseases of the Esophagus (ISDE), United European Gastroenterology (UEG), and European Society of Gastrointestinal Endoscopy (ESGE).